Oral Delivery of Bacillus subtilis Expressing Chicken NK-2 Peptide Protects Against Eimeria acervulina Infection in Broiler Chickens

Chicken NK-lysin peptide 2 (cNK-2) is a natural lytic peptide with direct cytotoxicity against many apicomplexan parasites including Eimeria. Developing an effective oral delivery strategy to express cNK-2 in the intestine, where Eimeria parasites interact with the host's gut epithelial cells, may effectively reduce the fecundity of parasites and minimize intestinal damage. Furthermore, cNK-2 modulates gut immune responses to decrease local inflammation elicited by Eimeria infection in the intestine. Therefore, we developed a stable strain of Bacillus subtilis (B. subtilis) that carries cNK-2 to the gut to determine its effectiveness in ameliorating the negative impacts of coccidiosis and to replace the use of antibiotics in controlling coccidiosis in commercial broiler chicken production. Chickens were randomly allocated into eight treatment groups: two control groups (NC: E. acervulina infected non-B. subtilis control; CON: non-infected control); three B. subtilis-empty vector (EV) groups (EV6: 106 cfu/day/bird; EV8: 108 cfu/day/bird; EV10: 1010 cfu/day/bird), and three B. subtilis-cNK-2 groups (NK6: 106 cfu/day/bird; NK8: 108 cfu/day/bird; NK10: 1010 cfu/day/bird). All chickens, except those in the CON group, were challenged with 5,000 freshly sporulated E. acervulina oocysts through oral gavage on day 15. Chickens were given an oral dose of B. subtilis on days 14, 15, and 16. Body weight, weight gains, and fecal oocyst shedding were measured. To investigate the efficacy of oral B. subtilis-cNK-2 against coccidiosis, gene expression of gut health-related biomarkers was measured using RT-PCR. Markers included SOD1, CAT, and HMOX1 for oxidative stress in the spleen and intestinal mucosa, OCLN, ZO-1, and JAM2 for tight junction proteins, and MUC2 for mucin gene expression in the gut. The results showed that oral treatment of young chickens with B. subtilis-cNK-2 improved growth performance, enhanced gut integrity, and reduced fecal oocyst shedding. Altogether, these results confirm B. subtilis-cNK-2 treatment as a promising and effective alternative strategy to replace antibiotics against coccidiosis based on its ability to reduce parasite survival, to reduce coccidiosis-induced body weight loss, and to decrease gut damage based on the enhanced expression of proteins associated with gut integrity and intestinal health.

Chicken NK-lysin peptide 2 (cNK-2) is a natural lytic peptide with direct cytotoxicity against many apicomplexan parasites including Eimeria. Developing an effective oral delivery strategy to express cNK-2 in the intestine, where Eimeria parasites interact with the host's gut epithelial cells, may effectively reduce the fecundity of parasites and minimize intestinal damage. Furthermore, cNK-2 modulates gut immune responses to decrease local inflammation elicited by Eimeria infection in the intestine. Therefore, we developed a stable strain of Bacillus subtilis (B. subtilis) that carries cNK-2 to the gut to determine its effectiveness in ameliorating the negative impacts of coccidiosis and to replace the use of antibiotics in controlling coccidiosis in commercial broiler chicken production. Chickens were randomly allocated into eight treatment groups: two control groups (NC: E. acervulina infected non-B. subtilis control; CON: non-infected control); three B. subtilis-empty vector (EV) groups (EV6: 10 6 cfu/day/bird; EV8: 10 8 cfu/day/bird; EV10: 10 10 cfu/day/bird), and three B. subtilis-cNK-2 groups (NK6: 10 6 cfu/day/bird; NK8: 10 8 cfu/day/bird; NK10: 10 10 cfu/day/bird). All chickens, except those in the CON group, were challenged with 5,000 freshly sporulated E. acervulina oocysts through oral gavage on day 15. Chickens were given an oral dose of B. subtilis on days 14, 15, and 16. Body weight, weight gains, and fecal oocyst shedding were measured. To investigate the efficacy of oral B. subtilis-cNK-2 against coccidiosis, gene expression of gut health-related biomarkers was measured using RT-PCR. Markers included SOD1, CAT, and HMOX1 for oxidative stress in the spleen and intestinal mucosa, OCLN, ZO-1, and JAM2 for tight junction proteins, and MUC2 for mucin gene expression in the gut. The results showed that oral treatment of young chickens with B. subtilis-cNK-2 improved growth performance, enhanced gut integrity, and reduced fecal oocyst shedding. Altogether, these results confirm B. subtilis-cNK-2 treatment as a promising and effective alternative strategy to replace antibiotics against coccidiosis based on its ability to reduce parasite survival, to reduce coccidiosis-induced body weight loss, and to decrease gut damage based on the enhanced expression of proteins associated with gut integrity and intestinal health.

INTRODUCTION
Coccidiosis is a major enteric disease of chickens that is caused by several distinct species of Eimeria protozoan parasites infecting different areas of the gut. Coccidiosis primarily damages epithelial integrity in the intestine decreasing nutrient utilization and resulting in an annual loss of over $3.2 billion in the poultry industry globally (1)(2)(3). With the onset of coccidiosis, Eimeria elicits a local inflammatory response in the intestine, increasing gut permeability, and poor nutrient absorption that hinders optimal growth performance (2,4). A live attenuated coccidiosis vaccine is a cost-effective approach currently utilized to control coccidiosis in commercial poultry. However, the inability to induce consistent protection, evidence of residual virulence, increasing incidence of drug resistance in Eimeria, and strict governmental regulation of in-feed medication in poultry production prompt the discovery of alternative strategies to control coccidiosis to support "no antibiotics ever" or "antibioticfree" meat production for the poultry industry (5).
Alternative strategies to antibiotics, including recombinant vaccines, hyperimmune IgY antibodies, probiotics, prebiotics, phytochemicals, and antimicrobial peptides (AMPs) have been shown to reduce the clinical symptoms of poultry diseases, to enhance host innate immunity, and growth performance at various levels of efficacy (6)(7)(8). These alternatives have also been shown to control coccidiosis in commercial poultry by maintaining gut health and enhancing immunity. Among these alternatives, AMPs are small peptides that may have direct cytotoxic effects against various pathogens, including parasites such as Eimeria (1,9). The amphipathic structure of AMP molecules easily destroys a wide range of pathogens by interacting with negatively charged cationic residues (7,9,10).
NK-lysin is a cationic amphiphilic AMP originally identified in Natural killer (NK) cells of porcine intestinal tissue and later characterized in chicken (1,11). NK-lysin has a globular structure with 78 amino acid residues and is orthologous to human granulysin. NK-lysin, like other members of the saposinlike protein family, exhibits cytolytic activities against tumor cells and microbes (12). NK-lysin also mediates immune regulation at low doses, which may play a pivotal role in the induction of adaptive immunity and regulation of inflammatory response (9).
Chicken NK-lysin (cNK-2) is a natural lytic peptide that has been reported to have effective cytotoxicity against apicomplexan parasites such as Eimeria by disrupting the sporozoite membrane (9,12). Chicken NK-2 derived from the cationic core region of the NK-lysin protein that is secreted from chicken cytotoxic lymphocytes during coccidiosis (10,12,13). The characterization and expression of cNK-2 have been previously studied and welldocumented (10,13). Additionally, cNK-2 has been shown to successfully destroy Eimeria spp. in both in vitro and in vivo studies (1).
Even though the structure and function of cNK-2 have been studied extensively, a major gap remains the discovery of an effective oral delivery strategy to preserve the functional activity of cNK-2 in the chicken gut under commercial operations. Without an effective delivery system, AMPs may lose their activity with the presence of enzyme degradation in the gut (9).
In a sustainable delivery system, AMPs not only promote host local immunity but also reduce parasite growth and promote a healthy gut microbial community. Moreover, an effective industry-friendly delivery strategy for antibiotic alternatives will reduce the cost of labor and increase the effectiveness of antibiotic-free animal production.
Gram-positive B. subtilis is generally recognized as a highly resistant microbe to environmental stresses, stable, and safe environmental bacterium uniquely qualified for oral delivery of peptides (14,15). B. subtilis can transit through the digestive tract, and the self-assembly structure of Bacillus spores demonstrate its superior ability to work as a successful delivery vehicle (16). In previous studies, recombinant B. subtilis spores with different protein expression levels were studied as a promising approach for sustainable delivery systems for mice, swine, and aquaculture (14,17,18).
To our knowledge, this is the first time B. subtilis has been explored for cNK-2 peptide delivery to the gut in chickens as a prevention strategy against coccidiosis. Therefore, we developed a stable strain of probiotic B. subtilis expressing cNK-2 to investigate its effectiveness as a carrier of cNK-2 to the gut and to explore its protective effect against coccidiosis challenge infection in commercial broiler chickens. In addition to evaluating the impact on growth and clinical signs caused by coccidiosis, we also evaluated gut integrity and immunity by looking at the presence of tight junction transcripts and antioxidative responses.

Recombinant B. subtilis Construction
Recombinant B. subtilis spores expressing empty vector (B. subtilis-EV) or B. subtilis-cNK-2 were constructed and provided by US Biologic (Memphis, TN). The NK-lysin used for the expression in a bacterial vector was based on the chicken NK-lysin sequence (RRQRSICKQLLKKLRQQLSDALQNNDD) reported previously (1,9), which was then cloned into the pTTB2 expression vector (MoBiTec). Briefly, pTTB2-cNK was then expanded in BL21 competent E. coli (New England Biolabs, Inc., Ipswich, MA) and purified using the GeneJET Plasmid Miniprep Kit (Thermo Fischer Scientific, Madison, WI). Sequences were confirmed using Sanger sequencing and purified plasmids were religated using the Rapid DNA Ligation (Thermo Fisher Scientific, Madison, WI). Competent B. subtilis cells (strain WB800N, MoBiTec) were transformed using 0.1 M EGTA and expanded on agar plates using 2% xylose as a selection agent. Single colonies were sequenced and expanded using 2xYT media (Difco, BD Diagnostic Systems, Sparks, MD).

In vitro Killing Assays
B. subtilis-EV and B. subtilis-cNK-2 were grown in media and culture supernatants tested for anti-sporozoite activity using an in vitro assay as described (19). Briefly, sporocysts from freshly sporulated E. acervulina oocysts were harvested and purified using isopycnic centrifugation on a Percoll gradient followed by washing with ice-cold phosphate-buffered saline. Next, sporocysts were treated with excystation solution (0.25% trypsin, 0.014 M taurocholic acid) and incubated for 30 min at 41 • C to release sporozoites. Afterward, sporozoites were harvested by filtering the excystation solution and washed with Hank's balanced salt solution (HBSS; Sigma-Aldrich, St. Louis, MO, USA). E. acervulina sporozoites (1.0 × 10 7 /mL) were mixed with the culture supernatant from B. subtilis-EV or B. subtilis-cNK-2 culture in a 1:1 ratio. Recombinant cNK-2 (Genscript, Piscataway, NJ) was used as control at a concentration of 100 µg/mL. After 3 h incubation at 41 • C, the sporozoites were stained with fluorescence viability dye (AO/PI staining solution, Nexcelom Bioscience LLC, Lawrence, MA), and viable sporozoites were counted microscopically.

Chickens and Animal Care
Eighty one-day-old Ross broiler chicks (Ross 708) were obtained from a local hatchery (Longnecker Hatchery, Elizabethtown, PA) and housed in Petersime brooder units maintained in a temperature-controlled closed-house environment. Chickens were raised to 14 days of age with non-medicated commercial starter diets. After 14 days, chickens were moved to experimental grower cages and fed a non-medicated commercial grower diet until the end of the experimental period. Ad libitum feeds and fresh clean water were provided at all times.

Body Weight and Sample Collection
Individual body weights were recorded for all chickens on day 14, 17, 21, 24, and 28. Pooled fecal samples were collected from each cage daily from day 21 (6 dpi) until day 24 (9 dpi). At the end of the experiment (28 days; 13 dpi), five birds from each treatment group were randomly selected for intestinal sample collection. Chickens were humanely sacrificed by cervical dislocation, and the spleen and the mucosa of mid-duodenum tissue were dissected and stored in RNAlater TM (Invitrogen Corporation, Carlsbad, CA) at −20 • C.

Fecal Oocyst Assessment
The collected fecal samples were processed according to the method previously described (21). Briefly, feces collected from individual cages were ground and homogenized with 3 L of water. Two subsamples from each cage were put into 50 mL tubes for oocyst counting. To count fecal oocysts, various dilutions were made initially to determine the optimum dilutions for enumeration of oocysts for each sample. Three different scientists independently counted oocysts microscopically using Frontiers in Veterinary Science | www.frontiersin.org a McMaster counting chamber using a sodium chloride flotation method as described (21). The total number of oocysts shed per chicken was calculated using the following formula: Total oocysts/bird = (oocyst count × dilution factor × fecal sample volume/counting chamber volume) / number of birds per cage.

RNA Extraction and qRT-PCR
Collected tissue samples were gently washed with ice-cold HBSS (Sigma-Aldrich, St. Louis, MO, USA) and homogenized using a handheld homogenizer (TissueRuptor; Qiagen, Hilden, Germany). Total RNA was extracted using TRIzol reagent (Invitrogen) followed by DNase digestion as described (5). Quantification and purity were assessed using a NanoDrop spectrophotometer (NanoDrop One; Thermo Scientific) at 260/280 nm. Synthesis of cDNA was performed using a QuantiTect R Reverse Transcription Kit (Qiagen) according to the manufacturer's instructions. The gene expression levels of tight junction proteins such as junctional adhesion molecule 2 (JAM2), occluding (OCLN), and zonula occludens-1 (ZO1), mucin 2 (MUC2) expression in the duodenum samples, and antioxidant markers including superoxide dismutase 1 (SOD1), heme oxygenase 1 (HMOX1), and catalase (CAT), in both duodenum and spleen samples were investigated. All oligonucleotide primer sequences used in this experiment are shown in Table 2. The cDNA samples were diluted to 1:5 and 5-µL aliquots were used for qRT-PCR amplification. The sample was analyzed using SYBR Green qPCR Master Mix (PowerTrack, Applied Biosystems, Vilnius, Lithuania) in triplicate using Applied Biosystems QuantStudio 3 Real-Time PCR Systems (Life Technologies, Carlsbad, CA). The following PCR conditions were followed: denaturation at 95 • C for 10 min followed by amplification at 60 • C for 1 min for 40 cycles. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as the reference gene for gene expression. For relative quantification of the gene expression levels, the logarithmic-scaled threshold cycle (Ct) values were used in the 2 − Ct method before calculating the mean and standard error of the mean (SEM) for the references and individual targets.

Statistical Analysis
Data were analyzed using Mixed Model (PROC MIXED) in SAS (SAS Inc., Cary, NC). The individual chicken was considered the experimental unit for statistical analysis. The results are given as least-squares means and pooled SEM. P-values < 0.05 were considered to be significant. When the p-value between treatments was <0.05, homogeneous subsets were evaluated by the PDIFF option in SAS. The dose-response of growth performances were determined using the Interactive Matrix Language (IML) procedure of SAS to generate coefficients for the evenly spaced orthogonal contrasts. These coefficients generated by the IML procedure were then used in the mixed procedure for contrasts.

In vitro Assay for Sporozoite Viability
Sporozoites treated with cNK-2 (control) showed a significant decrease (p < 0.05) in sporozoites viability at the end of the 3 h incubation period (Figure 2). Culture supernatant from B. subtilis-cNK-2 also showed a similar (p > 0.05) sporozoites killing activity compared to control. However, sporozoites treated with the culture supernatant from B. subtilis-EV showed higher viability (p < 0.05) compared to control and the group treated with B. subtilis-cNK-2 culture.

Body Weight and Daily Gain
Body weights of all chickens did not significantly differ (day 14: p > 0.05) between groups at the start of the trial ( Table 3). There were no significant changes (p > 0.05) between treatments at day 17 (2 dpi) regardless of E. acervulina infection or the type and dose of B. subtilis administration. Chickens infected with E. acervulina showed lower (p < 0.05) body weight at day 21 (6 dpi) than the CON chickens. However, the body weights of chickens in the NK10 group were significantly higher (p < 0.05) than those of NC chickens at day 24 (9 dpi). Chickens that received EV did not show (p > 0.05) any dose responses for body weight measurement throughout the study period. In contrast, chickens in the NK groups showed enhanced body weights in a dose-dependent manner (p < 0.05) at day 21 and 24. Similar to the body weight data, no significant changes (p > 0.05) were seen in the average daily gain (ADG) of chickens among the different treatment groups up to day 17 (2 dpi) ( Table 3). Thereafter, chickens infected with E. acervulina showed significantly lower (p < 0.05) ADG than the CON group. However, chickens in the NK10 group showed significantly increased (p < 0.05) ADG compared to that of the NC group from day 17 to 24 (2-9 dpi). After day 24, the NK10 group did not show any significant difference (p > 0.05) in ADG compared to the NC chickens regardless of NK treatment dose.

Fecal Oocyst Shedding
Chickens that were treated with an oral dose of B. subtilis-cNK-2 showed significantly reduced (p < 0.05) fecal oocyst output between 6 and 9 dpi (Figure 3). In particular, the NK10 group showed significantly decreased (p < 0.05) oocyst shedding compared to the NC group.

Gene Expression of TJ Proteins and Mucin
Gene expression profiles of tight junction proteins in the duodenal mucosa are shown in Figure 4. On 13 dpi, chickens in the NC group did not show any significant difference (p > 0.05) in the expression levels of OCLN, ZO-1, and JAM-2 compared to the CON group. However, chickens that were given B. subtilis-cNK-2 (NK6, NK8, and NK10) showed increased (p < 0.05) OCLN gene expression compared to the NC chickens, regardless of doses of NK-lysin treatment. In comparison to B. subtilis-cNK-2 and B. subtilis-EV, no difference (p > 0.05) was observed in OCLN gene expression for each dose. Moreover, chickens in the NK8 and NK10 groups showed higher (p < 0.05) expression of ZO-1 than chickens in the NC, EV8, and EV10 groups. Similarly, JAM-2 expression in the duodenum was higher (p < 0.05) in the NK8 and NK10 treatment groups than in the EV8 and EV10 groups. Notably, MUC2 gene expression was lower (p < 0.05) in NC chickens than in CON chickens but increased in the EV6, EV10, and NK6 groups compared to NC chickens. Figure 5 shows the mucosal antioxidant gene expression profile in the duodenum. Chickens treated with B. subtilis-cNK-2 (NK6, NK8, and NK10) and infected with E. acervulina showed elevated (p < 0.05) expression of HMOX1 in the duodenal mucosa ( Figure 5C) compared to the chickens in the E. acervulina-infected control (NC) group. There was no significant difference (p > 0.05) in the expression levels of the SOD1 and CAT genes in the duodenal mucosa at 13 dpi (Figures 5A,B).

Antioxidant Gene Expression in Spleen
Gene expression profiles of antioxidant genes in the spleen are shown in Figure 6. The expression of CAT and HMOX1 was higher (p < 0.05) in the CON group than in the NC and EV groups. Notably, chickens orally treated with higher doses of B. subtilis-cNK-2 (NK8 and NK10)  showed similar (p > 0.05) levels of expression as those of the CON group.

DISCUSSION
Antibiotic alternatives including host defensin proteins such as NK-lysin are becoming important feed additives for the animal industry in the post-antibiotic era (22). Antimicrobial peptides elicit first-line defense against pathogens in livestock animals and are recognized as a potential antibiotic alternative (9,12). Among these peptides, the cNK-lysin peptide was reported to exert antibacterial activity by damaging bacterial cells (12). Nevertheless, information concerning the efficient delivery systems to deliver these AMPs to the gut are scantly documented in poultry and livestock. Hence, the development of an effective oral delivery system that could deliver AMP across the gut lumen and stimulate immune responses is needed. To this end, this study was conducted to determine the effectiveness of stable B. subtilis that carries cNK-2 peptide (B. subtilis-cNK-2) as a carrier of NK-lysin peptide to the chicken gut and to investigate its effect against E. acervulina infection in commercial broiler chickens. To the best of our knowledge, this study is the first to investigate and describe the potential effectiveness of oral delivery of stable B. subtilis as a carrier for the cNK-2 peptide against coccidiosis infection in chickens.
Diversified approaches based on nanoparticles, natural polysaccharides, bacteria, and phages have been reported as promising delivery vehicles for AMPs (23,24). Among these AMP delivery systems, B. subtilis has shown unique properties as an effective carrier for AMPs in previous studies with fish, mice, and swine (14,17,18). Higher stability and extreme resistance to harsh environments, non-pathogenic nature, and ability to produce an industrial scale are the uniqueness of B. subtilis as an attractive delivery system (14,16).
To achieve our study objective, we followed the mode of action based on the NK-lysin peptide, which displays strong cytotoxicity against E. acervulina as a consequence of altering the sporozoite outer membrane integrity and releasing intracellular contents (1). Controlling E. acervulina sporozoites invading gut epithelial cells will reduce gut damage and minimize production losses due to coccidiosis. Our in-vitro assay confirmed that the culture supernatant from B. subtilis-cNK-2 but not B. subtilis-EV contained anti-sporozoite activity against freshly prepared sporozoites.
In the present study, chickens in the Eimeria-infected control treatment showed lower growth performance than their counterpart chickens in the uninfected control, as expected. Chickens infected with E. acervulina showed reduced growth performance because of the interruption of normal gut physiology and nutrition metabolism (20,25). Rochell et al. (26) and Kim et al. (27) also reported that E. acervulina infection reduces growth performance in broiler chickens. Our results show that B. subtilis-cNK-2 treatment had a significant positive effect on the growth performance of coccidia-infected broiler chickens. Importantly, there was no growth improvement in chickens given an oral dose of B. subtilis-EV and infected with E. acervulina confirming that cNK-2 delivered by B. subtilis is responsible for reduced parasite fecundity and minimal growth depression in response to coccidia challenge in chickens. Consistent with our findings, Lee et al. (1) reported improved body weight gain in E. acervulina-infected and cNK-2 peptidetreated broiler chickens. Findings from this study showing that the cNK-2 directly improved growth performance provides a strong indication that a stable B. subtilis delivery system is a promising way to preserve cNK-2 functionality in the chicken gut. It was also noticeable that the effect of E. acervulina infection on growth performance was more profound at the early stage of post-infection and was not significant in the later stages of the infection. These findings may be observed because the infection effect was reduced, and chickens began a recovery phase.
Enumeration of oocyst shedding in fecal samples is a commonly used measurement for understanding the severity of coccidiosis infections in broiler chickens. The reduction of oocysts is also used as a tool to determine the protective indices of different anti-parasite strategies against Eimeria invasion. In this study, E. acervulina-infected chickens exhibited elevated fecal oocyst shedding, confirming the establishment of Eimeria in the chicken gut. Chickens that were administered an oral dose of B. subtilis-EV showed numerically lower oocyst shedding than the infected control chickens, although no statistical significance was reached. Importantly, chickens that were given an oral dose of B. subtilis-cNK-2 showed a negative dose-dependent response to fecal oocyst shedding. Chickens given B. subtilis-cNK-2 at 10 10 cfu/day showed significantly lower oocyst shedding at 9 dpi than untreated infected control. This outcome supports the direct effect of cNK-2 activity against Eimeria which confirms our previous work (1,28). This indicates that the B. subtilis-cNK-2 at 10 10 cfu/day can be used as a remedial measure to control coccidiosis in the poultry industry. By preserving cNK-2 activity against Eimeria parasites in the chicken gut environment, B. subtilis carriers are an effective and practical oral delivery vehicle for immunotherapeutic peptides such as AMP.
Tight junctions of gut epithelial cells work as a first-line defense system to protect animals from pathogen translocation by maintaining proper tight junction integrity (29). Tight junctions are comprised of a multiprotein complex, such as OCLN, ZO-1, and JAM-2, at the apical end of epithelial cells that closely contact with the lumen (4,30). Maintaining epithelial integrity by maintaining intestinal permeability enhances the gut health of chickens and nutrient absorption to improve growth performance (30). Based on our current study, higher dosages of B. subtilis-cNK-2 increased tight junction gene expression in the duodenal mucosa compared to the infected control group. Recently, we showed that upregulation of these genes improved gut barrier function in the chicken intestine after E. acervulina infection (5). Moreover, elevated levels of ZO-1 and JAM-2 gene expression in chickens that were treated with higher dosages of B. subtilis-cNK-2 compared to control B. subtilis-EV demonstrated reduced damage by coccidiosis on gut barrier functions. Similar to tight junctions, the mucosal barrier defends against the invasion of bacteria, parasites, and other harmful species into the host (7). Mucins are glycoproteins that form a mucus barrier over the epithelial cell surfaces of the intestine (31,32). Among mucins, MUC-2 gene expression has been identified as a gut health marker in chicken and other poultry species, as it is the major mucin produced by goblet cells (7,31). Our results indicate that E. acervulina-infected chickens showed significantly decreased mucosal MUC-2 gene expression levels compared to the non-infected control. This result provides firm confirmation of mucus barrier failure in chickens challenged with coccidiosis. Chickens that were given an oral dose of B. subtilis-cNK-2 counteracted E. acervulina infection-induced MUC-2 downregulation and increased its expression. This finding confirms previous studies showing increased MUC-2 gene expression in chickens fed B. subtilis as a probiotic supplement (4,7,33).
Previously, it was reported that coccidiosis triggers oxidative stress, thereby weakening intestinal barrier functions in chickens (34). For a robust understanding of gut health improvement with B. subtilis-cNK-2, we also investigated mucosal oxidative stress markers. Higher production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) cause imbalances between free radical production and endogenous antioxidant defense, creating oxidative stress in intestinal cells and leading to lipid peroxidation, DNA damage, and apoptosis (34). Avoiding oxidative stress, free radical formation is prevented by the inactivation of precursors of free radicals or catalysts with the aid of enzymes, such as catalase, superoxide dismutase (SOD), and glutathione peroxidase (35). SOD enzymes catalyze the conversion of superoxide ions (O − 2 ) to hydrogen peroxide (H 2 O 2 ) and oxygen (O 2 ) (4), whereas CAT enzymes catalyze the breakdown of hydrogen peroxide (H 2 O 2 ) to H 2 O and O 2 (35). HMOX1 is a rate-limiting enzyme responsible for heme-tobiliverdin catabolism (36). In this study, we did not observe any significant differences in SOD1 and CAT gene expression levels in the duodenal mucosa. However, significantly upregulated HMOX1 gene expression was observed in the duodenal mucosa from the B. subtilis-cNK-2-treated chickens compared to the untreated infected control. Compared to the mucosa, the spleen showed more pronounced antioxidant gene expression even though SOD1 expression remained unchanged. Both CAT and HMOX1 expression levels in the spleen were elevated with B. subtilis-cNK-2 treatments in this study. Although elevated expression levels of CAT and HMOX1 in the B. subtilis-cNK-2 treated group was not significantly different from those in the infected control group, the results support the notion that cNK-2 reduced the oxidative stress induced by E. acervulina infection.

CONCLUSION
This study shows the effectiveness of a stable B. subtilis carrying the cNK-2 as an oral delivery method for NK-lysin peptide to the E. acervulina-infected chicken gut, which resulted in improved growth performance via enhanced gut integrity and reduced oocyst shedding. These results also help to characterize the ability of cNK-2 to reduce oxidative stress induced by E. acervulina infection in chickens. These findings indicate the need for future studies on the mechanisms of the B. subtilis carrier system for successful AMP delivery and research on the NKlysin approach as a strategy to reduce the coccidiosis-induced gut pathology in chickens. Further research characterizing the responses of higher doses of B. subtilis that carry cNK-2 together with different administration intervals and mode of delivery of Bacillus spores using different Eimeria challenges is warranted to develop effective commercializable strategies to replace antibiotics.

DATA AVAILABILITY STATEMENT
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT
The animal study was reviewed and approved by Beltsville Agricultural Research Center Small Animal Care Committee (Animal Protocol No. 20-002).

AUTHOR CONTRIBUTIONS
HL, JO, IP, WK, and CG designed the research. IP, SW, WK, and YL conducted the research and analyzed data. JO produced and provided test materials for studies. SW, CG, and HL drafted the manuscript, and all authors reviewed and edited the manuscript to its final version. SW, IP, YL, WK, JO, CP, CG, and HL had responsibility for the content. All authors contributed to the article and approved the submitted version.